A San Francisco company putting FDA-cleared wearables on expecting mothers and feeding what they hear straight to the clinicians who need it most.
Inside is a cellular-enabled kit - a wearable that listens for two heartbeats, a cuff for blood pressure, a meter for glucose. No app store login marathon, no waiting room, no four-hour round trip on the day of a routine check. The mother sticks on the sensor at her kitchen table. Somewhere else, a clinician's screen quietly fills with data that used to require her to be in the room.
That is Bloomlife in 2026: not a gadget company, not a hospital, but the wire between the two. It takes pregnancy monitoring - a practice still run, in many places, the way it was run in 1970 - and moves it to wherever the patient happens to be. The company calls the problem "maternity care deserts." Most people just call it living too far from a doctor.
"Current practices in maternal healthcare are often outdated, relying heavily on frequent in-person appointments."
- Eric Dy, Co-Founder & CEOBloomlife exists because of a bad month. Co-founder Eric Dy's wife had a high-risk pregnancy - placental complications, gestational diabetes, preeclampsia, a preterm birth. Their newborn son spent his first month of life in the NICU. Dy, who had spent his career in sensors and data, did what engineers do with grief: he tried to fix the system that scared him.
He teamed up with Julien Penders, a wearable-sensor researcher out of Belgium, and in 2014 the two launched the company. The first product was charming and consumer-friendly - a medical-grade patch that let expecting mothers feel, and chart, their own contractions. Roughly 15,000 women used it. It was a hit on the CES floor and a quiet data-collection machine in the background.
Then the FDA wanted more oversight, and the romance of a direct-to-consumer wearable ran into the arithmetic of medical regulation. Most startups would have flinched. Bloomlife pivoted - hard - from selling a gadget to expecting parents to selling a clinical platform to the health systems that care for them.
The bet underneath all of it is unfashionably simple: that the data a mother generates at home is more useful in a doctor's hands than in her own. It is less Instagrammable than a glowing belly-band. It is also the version that gets reimbursed.
The FDA-cleared wearable that monitors maternal and fetal heart rates at once - the kind of fetal surveillance that used to mean a trip to labor & delivery, now done at home.
Cellular kits ship to patients' homes; the readings flow back into clinical systems with risk-stratification and automated alerts so the right pregnancy gets attention first.
Remote monitoring programs for blood pressure and glucose during pregnancy - with maternal mental health and social-determinants screening on the roadmap.
The contraction-tracking wearable that started it all. Retired from retail, but it seeded one of femtech's larger real-world maternal datasets and a labor-onset algorithm.
| Round | Amount | When | Notable Backers |
|---|---|---|---|
| Seed | $4M | 2016 | Early digital-health investors |
| Series A | $12.2M | Sep 2024 | Kapor Capital, Noshaq, RH Capital, 15th Rock, The Grove Foundation |
The 2024 round, led by Kapor Capital and Belgian investor Noshaq, is earmarked for two things: pushing the commercial platform wider, and developing - then clearing - a second proprietary device. Reading between the lines, that is a company that has decided regulation is not the enemy but the moat.
Eric Dy and Julien Penders start the company after Dy's own high-risk pregnancy experience.
The consumer patch reaches roughly 15,000 mothers and shows up at CES.
Regulatory reality reshapes the model from gadget sales to enterprise clinical monitoring.
A wearable cleared to monitor maternal and fetal heart rate at home.
Kapor Capital and Noshaq lead a round to fund expansion and a second device.
PeriGen on care-desert access; the UCSF Preterm Birth Initiative on technology for communities of color; deployments and pilots with provider groups including UCHealth, OHSU, Ochsner, Unified Women's Healthcare and Valley Perinatal Services.
FDA clearance for MFM-Pro, SOC 2 Type 2 compliance, reimbursement across 18 payers, and recognition from CES, NSF, AFWERX, MedTech Innovator and the J&J QuickFire challenge.
"The healthcare industry increasingly recognizes the need for efficient, accessible, and patient-centered care models."
- Eric Dy, Co-Founder & CEOBloomlife shares the femtech maternity lane with names like Babyscripts, Nuvo (INVU), Owlet's BabySat, and GE HealthCare's Novii - plus the incumbent it is really competing with: the in-clinic monitor that assumes the patient can always get to the clinic.
The box still arrives at the door three hours from the nearest OB. The difference is that now, someone on the other end is already watching.